Free tool
FAERS Monitor: Natroba
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022408 or its brand name (Natroba, Spinosad). Reports on generic versions are filed under their own applications.
Reports
47
Serious
13
28% of reports
Hospitalization
2
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective15
- pruritus7
- alopecia5
- rash4
- condition aggravated3
- erythema3
- abdominal pain upper2
- burning sensation2
- death2
- headache2
- lice infestation2
- paraesthesia2
- product quality issue2
- seizure2
- sleep disorder2
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 3 |
| 2012 | 8 |
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 4 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,112 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| lice infestation | 2 | 4307.3 | 1102.3 | 4,797 |
| burning sensation | 2 | 12.8 | 3.3 | 12 |
| sleep disorder | 2 | 12.7 | 3.3 | 11 |
| alopeciaSignal | 5 | 11.4 | 5.0 | 38 |
| pruritusSignal | 7 | 8.2 | 4.1 | 38 |
| seizure | 2 | 7.7 | 2.0 | 6 |
| product quality issue | 2 | 6.6 | 1.7 | 5 |
| erythemaSignal | 3 | 6.5 | 2.2 | 9 |
| paraesthesia | 2 | 5.7 | 1.5 | 4 |
| drug ineffectiveSignal | 15 | 5.1 | 3.4 | 48 |
| condition aggravatedSignal | 3 | 4.4 | 1.5 | 5 |
| abdominal pain upper | 2 | 4.3 | 1.1 | 2 |
| rashSignal | 4 | 4.1 | 1.6 | 7 |
| headache | 2 | 1.4 | 0.4 | 0 |
| death | 2 | 1.0 | 0.3 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.